March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide) to reduce the risk of major cardiovascular ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...
March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional ...
February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...
February 6, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...
January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...
January 12, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...
November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...
November 24, 2023 — During the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA, Mi ...
November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...
November 10, 2023 — Silence Therapeutics plc, an experienced and innovative biotechnology company committed to ...
In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...
In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...
In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based ...
August 30, 2023 — BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro ...